RANI · Rani Therapeutics Holdings, Inc.
$0.84
+0.02 (+3.00%)
At close · Jul 29
Market Cap
$104.54M
Shares
123.88M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.84
Open$0.81
Day$0.79–0.87
52W$0.44–3.87
Avg vol 30d915K
Short int8.8M · 7.1% float · 11.3d
Short vol72%
Last earningsMar 26, 2026
DataJul 2021–Jul 2026
Filing10-Q · May 15
Up next
Next earnings call
Mar 23, 2027
Est · unconfirmed
· in 34 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
+4%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
−29%
trailing
YTD return
−37%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
13 of 76 funds reported for Jun 30 · net -6.0K sh shares
Insider flow
Accumulating
Net +$50.0K over 90 days · 0% sells
Short interest
Falling
7.14% of float · ▼ -2.6% MoM · 11.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
76 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+59%
Y/Y
EPS growth
+57%
Y/Y
Free cash flow
$-18.8M
Balance sheet
$18.6M
net cash
Quant / Vol
risk profile
Volatility
273%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
13 of 76 funds reported for Jun 30 · net -6.0K sh shares
Insider flow
Accumulating
Net +$50.0K over 90 days · 0% sells
Short interest
Falling
7.14% of float · ▼ -2.6% MoM · 11.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
76 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $1 · 12%
52-wk high $4
vs 200-day avg -30%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RANI
this stock
Rani Therapeutics Holdings, Inc.
|
$104.54M | -37.5% | +58.9% | — | 7.1% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RANI | -5.9% | +11.0% | -29.1% | +11.0% | -37.5% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -4.9% | +11.0% | -36.5% | +11.8% | -46.1% |
Key facts
CIK
1856725
CUSIP
753018100
13F (30d)
13 filings
12 filers
Visit website
Investor relations